X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-04-17 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.04 | -88,888 | 0 | -100% | -$536,661 | |||||
| D | 2024-04-16 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $25.74 | -1,750 | 1,737 | -50% | -$45,045 | |||||
2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $7.66 | -11,447 | 7,229,861 | 0% | -$87,725 | ||||||
| DM | 2024-04-16 | RXRX | Recursion Pharmaceuticals, Inc. | Secora Michael | CFO | S - Sale+OE | $7.63 | -48,124 | 1,231,055 | -4% | -$367,007 | |||||
| D | 2024-04-16 | ACLX | Arcellx, Inc. | Ware Olivia C | Dir | S - Sale+OE | $55.55 | -9,402 | 0 | -100% | -$522,260 | |||||
| D | 2024-04-15 | OTLK | Outlook Therapeutics, Inc. | Syntone Ventures LLC | 10% | P - Purchase | $0.00 | +714,286 | 1,705,438 | +72% | +$0 | |||||
| DM | 2024-04-16 | HALO | Halozyme Therapeutics, Inc. | Labarre Michael J. | SVP, CHIEF TECHNICAL OFFICER | S - Sale+OE | $38.42 | -20,000 | 168,176 | -11% | -$768,390 | |||||
2024-04-16 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $2.50 | -17,238 | 172,432 | -9% | -$43,095 | ||||||
| D | 2024-04-15 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $59.91 | -19,582 | 408,122 | -5% | -$1,173,232 | |||||
| D | 2024-04-15 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $133.37 | -19,818 | 40,778 | -33% | -$2,643,020 | |||||
2024-04-15 | DNLI | Denali Therapeutics Inc. | Sato Vicki L | Dir | S - Sale | $18.29 | -1,666 | 118,043 | -1% | -$30,471 | ||||||
| D | 2024-04-15 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale+OE | $18.19 | -15,000 | 408,035 | -4% | -$272,871 | |||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| A | 2024-04-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193,548 | 616,541 | +46% | +$2,999,994 | |||||
| DM | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Haigh Adrian | COO | S - Sale+OE | $6.30 | -88,888 | 0 | -100% | -$559,848 | |||||
| M | 2024-04-01 | PROK | Prokidney Corp. | Weber Darin J. | SVP of Regulatory Development | S - Sale | $1.73 | -84,403 | 189,670 | -31% | -$146,005 | |||||
2024-04-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $105.02 | -15,000 | 1,642,290 | -1% | -$1,575,300 | ||||||
| D | 2024-04-15 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $10.45 | -800 | 45,838 | -2% | -$8,360 | |||||
2024-04-10 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $35.40 | -17,500 | 810,850 | -2% | -$619,467 | ||||||
2024-04-10 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $107.12 | -15,000 | 11,737,969 | 0% | -$1,606,865 | ||||||
| D | 2024-04-10 | RVMD | Revolution Medicines, Inc. | Patel Sushil | Dir | S - Sale+OE | $37.00 | -2,155 | 15,700 | -12% | -$79,735 | |||||
| M | 2024-04-09 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.88 | +3,188 | 1,086,279 | 0% | +$2,805 | |||||
2024-04-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $33.16 | -556 | 74,444 | -1% | -$18,434 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Barnett Eva Renee | CFO | S - Sale | $31.18 | -3,689 | 371,709 | -1% | -$115,023 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Butchko Julia G. | Chief Development Officer | S - Sale | $31.18 | -1,053 | 461,742 | 0% | -$32,833 | ||||||
2024-04-09 | IMVT | Immunovant, Inc. | Salzmann Peter | CEO | S - Sale | $31.18 | -4,807 | 1,086,958 | 0% | -$149,882 | ||||||
| A | 2024-01-29 | CGON | Cg Oncology, Inc. | Decheng Capital Global Life Sciences Fund Iv, L.P. | 10% | P - Purchase | $19.00 | +400,000 | 4,958,810 | +9% | +$7,600,000 | |||||
| D | 2024-04-08 | MRNA | Moderna, Inc. | Mock James M | CFO | S - Sale+OE | $101.93 | -705 | 5,048 | -12% | -$71,859 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Williams Charles O | CFO, COO | P - Purchase | $0.00 | +1,474 | 1,474 | New | +$0 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Parker Craig C | CEO | P - Purchase | $0.00 | +1,474 | 1,474 | New | +$0 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $15.50 | +193,548 | 627,652 | +45% | +$2,999,994 | |||||
| D | 2024-04-04 | SRZN | Surrozen, Inc./De | Column Group III Gp, LP | 10% | P - Purchase | $15.50 | +193,548 | 627,652 | +45% | +$2,999,994 | |||||
2024-04-04 | HLVX | Hillevax, Inc. | Frazier Life Sciences X, L.P. | 10% | P - Purchase | $14.50 | +8,850 | 8,544,187 | 0% | +$128,325 | ||||||
2024-04-03 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $101.69 | -15,000 | 11,752,969 | 0% | -$1,525,268 | ||||||
| M | 2024-04-03 | HLVX | Hillevax, Inc. | Kohli Aditya | Dir | S - Sale | $14.69 | -18,000 | 789,776 | -2% | -$264,467 | |||||
| DM | 2024-04-03 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $8.93 | -130,000 | 938,524 | -12% | -$1,160,900 | |||||
| M | 2024-04-03 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.91 | +17,378 | 1,083,091 | +2% | +$15,814 | |||||
| M | 2024-04-04 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $10.82 | -88,583 | 187,471 | -32% | -$958,669 | |||||
| D | 2024-04-02 | DNA | Ginkgo Bioworks Holdings, Inc. | Dmytruk Mark E. | See Remarks | S - Sale+OE | $1.05 | -51,169 | 865,079 | -6% | -$53,727 | |||||
2024-04-02 | ALVR | Allovir, Inc. | Miller Edward | GC | S - Sale | $0.77 | -368 | 513,409 | 0% | -$284 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Brainard Diana | CEO | S - Sale | $0.77 | -1,533 | 812,536 | 0% | -$1,183 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Hagen Brett R | Chief Accounting Officer | S - Sale | $0.77 | -281 | 78,572 | 0% | -$217 | ||||||
2024-04-02 | ALVR | Allovir, Inc. | Sinha Vikas | See Remarks, 10% | S - Sale | $0.77 | -885 | 17,816,240 | 0% | -$683 | ||||||
2024-04-03 | VIR | Vir Biotechnology, Inc. | De Backer Marianne | CEO | S - Sale | $9.46 | -72,995 | 678,457 | -10% | -$690,365 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $32.74 | -492 | 178,380 | 0% | -$16,106 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Banyai William | See Remark | S - Sale | $32.74 | -327 | 345,986 | 0% | -$10,705 | ||||||
| D | 2024-04-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $32.74 | -1,132 | 514,149 | 0% | -$37,057 | |||||
2024-04-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $32.74 | -129 | 81,004 | 0% | -$4,223 | ||||||
2024-04-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $32.74 | -229 | 92,421 | 0% | -$7,497 | ||||||
2024-04-02 | BIIB | Biogen Inc. | Singhal Priya | Head of Development | S - Sale | $213.09 | -93 | 4,886 | -2% | -$19,817 | ||||||
| M | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $31.02 | -23,687 | 70,060 | -25% | -$734,805 | |||||
2024-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $32.12 | -3,401 | 104,594 | -3% | -$109,240 | ||||||
2024-04-01 | BEAM | Beam Therapeutics Inc. | Burrell Terry-Ann | CFO | S - Sale | $32.12 | -5,446 | 70,137 | -7% | -$174,926 | ||||||
| D | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $32.13 | -18,102 | 1,161,343 | -2% | -$581,617 | |||||
| D | 2024-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Pres | S - Sale+OE | $32.12 | -4,534 | 169,616 | -3% | -$145,632 | |||||
| D | 2024-04-01 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $31.78 | -8,153 | 1,737 | -82% | -$259,102 | |||||
| D | 2024-04-02 | XLO | Xilio Therapeutics, Inc. | Gilead Sciences, Inc. | 10% | P - Purchase | $0.76 | +485,250 | 7,345,473 | +7% | +$368,790 | |||||
2024-04-02 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $8.82 | -11,447 | 7,241,308 | 0% | -$100,942 | ||||||
2024-04-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | S - Sale | $10.78 | -40,584 | 276,054 | -13% | -$437,451 | ||||||
2024-04-01 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | P - Purchase | $0.00 | +12,500 | 104,271 | +14% | +$0 | ||||||
2024-04-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | CEO | P - Purchase | $0.00 | +29,167 | 316,638 | +10% | +$0 | ||||||
2024-04-01 | ACLX | Arcellx, Inc. | Elghandour Rami | SEE REMARKS | S - Sale | $67.09 | -23,086 | 69,253 | -25% | -$1,548,887 | ||||||
| D | 2024-04-01 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $137.30 | -272 | 7,507 | -3% | -$37,346 | |||||
| D | 2024-04-01 | PCVX | Vaxcyte, Inc. | Eydelman Mikhail | SVP, GC, Corp Sec | S - Sale+OE | $66.73 | -1,667 | 30,597 | -5% | -$111,234 | |||||
2024-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $66.69 | -3,000 | 218,289 | -1% | -$200,066 | ||||||
2024-04-01 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale | $66.71 | -2,616 | 625,209 | 0% | -$174,502 | ||||||
| D | 2024-04-01 | IMCR | Immunocore Holdings Plc | St Leger Tina Amber | CHRO | S - Sale+OE | $64.06 | -4,375 | 0 | -100% | -$280,263 | |||||
2024-04-02 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | COO | S - Sale | $9.88 | -1,357 | 117,004 | -1% | -$13,407 | ||||||
2024-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Pres, CEO | S - Sale | $9.86 | -12,115 | 322,839 | -4% | -$119,454 | ||||||
2024-04-01 | VIR | Vir Biotechnology, Inc. | Hanly Ann M. | EVP, CTO | S - Sale | $10.05 | -2,711 | 132,081 | -2% | -$27,251 | ||||||
2024-04-01 | GILD | Gilead Sciences, Inc. | Parsey Merdad | Chief Medical Officer | S - Sale | $72.96 | -2,000 | 96,304 | -2% | -$145,920 | ||||||
2024-04-01 | DNLI | Denali Therapeutics Inc. | Krognes Steve E. | Dir | S - Sale | $20.50 | -92,500 | 897,341 | -9% | -$1,896,250 | ||||||
| D | 2024-03-28 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $10.10 | -65,000 | 1,043,524 | -6% | -$656,500 | |||||
| D | 2024-03-28 | AVXL | Anavex Life Sciences Corp. | Missling Christopher U | Pres, CEO | S - Sale+OE | $5.11 | -73,380 | 1,250,210 | -6% | -$374,972 | |||||
| M | 2024-03-27 | FRTX | Fresh Tracks Therapeutics, Inc. | Exploration Capital, LLC | 10% | P - Purchase | $0.90 | +54,574 | 2,037,426 | +3% | +$49,113 | |||||
2024-03-28 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale | $33.86 | -60,000 | 1,179,445 | -5% | -$2,031,402 | ||||||
2024-03-28 | HLVX | Hillevax, Inc. | McLoughlin Sean | COO | P - Purchase | $16.98 | +1,250 | 1,250 | New | +$21,225 | ||||||
2024-03-27 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $109.06 | -15,000 | 11,767,969 | 0% | -$1,635,864 | ||||||
| D | 2024-03-27 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $35.04 | -5,833 | 1,737 | -77% | -$204,410 | |||||
2024-03-27 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $7.70 | -348 | 341,498 | 0% | -$2,680 | ||||||
2024-03-28 | FNCH | Finch Therapeutics Group, Inc. | Smisek Jeffery A | Dir | S - Sale | $2.58 | -8,242 | 46,772 | -15% | -$21,246 | ||||||
2024-03-27 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $7.70 | -765 | 530,113 | 0% | -$5,891 | ||||||
2024-03-27 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $7.70 | -298 | 514,679 | 0% | -$2,295 | ||||||
2024-03-27 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $7.70 | -348 | 327,390 | 0% | -$2,680 | ||||||
| D | 2024-03-27 | VCEL | Vericel Corp | Zerbe Robert L Md | Dir | S - Sale+OE | $51.57 | -3,278 | 23,395 | -12% | -$169,046 | |||||
2024-03-28 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Dir | P - Purchase | $11.82 | +1,882 | 5,049 | +59% | +$22,242 | ||||||
2024-03-28 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.39 | +500 | 555,947 | 0% | +$195 | ||||||
2024-03-27 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $30.99 | -1,500 | 54,374 | -3% | -$46,481 | ||||||
2024-03-27 | VIR | Vir Biotechnology, Inc. | Lee Sung | EVP, CFO | S - Sale | $9.89 | -6,008 | 100,492 | -6% | -$59,404 | ||||||
| D | 2024-03-25 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $66.93 | -15,000 | 775,187 | -2% | -$1,003,978 | |||||
| D | 2024-03-26 | FENC | Fennec Pharmaceuticals Inc. | Rallis Chris A | Dir | S - Sale+OE | $10.97 | -2,114 | 45,249 | -4% | -$23,191 | |||||
2024-03-26 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | S - Sale | $10.90 | -13,975 | 91,771 | -13% | -$152,346 | ||||||
| DM | 2024-03-22 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale+OE | $70.06 | -46,815 | 8,938 | -84% | -$3,279,714 | |||||
| D | 2024-03-21 | LENZ | Lenz Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $15.03 | +998,009 | 4,014,094 | +33% | +$15,000,075 | |||||
| D | 2024-03-21 | EXEL | Exelixis, Inc. | Garber Alan M | Dir | S - Sale+OE | $24.01 | -19,205 | 35,703 | -35% | -$461,112 | |||||
2024-03-25 | FENC | Fennec Pharmaceuticals Inc. | Andrade Robert | CFO | S - Sale | $11.00 | -13,975 | 105,746 | -12% | -$153,690 | ||||||
| D | 2024-03-21 | RXRX | Recursion Pharmaceuticals, Inc. | Marriott Tina | Pres, COO | S - Sale+OE | $10.75 | -8,000 | 639,982 | -1% | -$85,980 | |||||
| D | 2024-03-21 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $145.06 | -5,000 | 7,507 | -40% | -$725,320 | |||||
2024-03-21 | ACLX | Arcellx, Inc. | Carroll Jill | Dir | S - Sale | $70.55 | -504,263 | 1,479,148 | -25% | -$35,575,755 | ||||||
2024-03-20 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale | $102.39 | -15,000 | 11,782,969 | 0% | -$1,535,820 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |